

VOLUME 29 NUMBER 1 January 2023

pISSN 2287-2728
eISSN 2387-285X

CLINICAL and MOLECULAR HEPATOLOGY

The forum for latest knowledge of hepatobiliary diseases



HCC incidence is decreasing in Korea
but increasing in elderly

Early changes in biomarkers predict HBsAg response
Baveno-VII predicts decompensation in cACLD

Letter to the Editor

Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”

Rujittika Mungmunpantip¹ and Viroj Wiwanitkit²

¹Private Academic Consultant, Bangkok, Thailand; ²Department of Research Center, Chandigarh University, Punjab, India

Keywords: COVID-19; Vaccines; Liver

Dear Editor,

We would like to share ideas on “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis.”¹ In contrast to liver transplant recipients, patients with chronic liver disease exhibited a good humoral response to the coronavirus disease 2019 (COVID-19) vaccination, according to Cheung et al.¹ We also agree that COVID-19 is helpful in immunogenicity. The immunological response of a vaccine recipient with an underlying medical condition may be different from that of a healthy individual. Potential confounding factors must be taken into consideration while interpreting the current report. Prior asymptomatic COVID-19 infection is a possibility, and is not unusual.² If there is no method to rule out prior cases of asymptomatic COVID-19, it would be challenging to evaluate the effectiveness of the vaccine.

Authors' contribution

RM: 50% ideas, writing, approval for submission; VW: 50% ideas, supervision, approval for submission

Conflicts of Interest

The authors declare no conflicts of interest.

REFERENCES

- Cheung KS, Mok CH, Mao X, Zhang R, Hung IF, Seto WK, et al. COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: a meta-analysis. *Clin Mol Hepatol* 2022;28:890-911.
- Joob B, Wiwanitkit V. Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. *J Prev Med Public Health* 2020;53:70.

Corresponding author : Rujittika Mungmunpantip

Private Academic Consultant, 111 Bangkok 122, Bangkok 103300, Thailand
Tel: +66-22564133662, Fax: +66-22564133662, E-mail: rujittika@gmail.com
<https://orcid.org/0000-0003-0078-7897>

Editor: Seung Up Kim, Yonsei University College of Medicine, Korea

Received : Oct. 21, 2022 / **Received :** Oct. 26, 2022 / **Accepted :** Oct. 26, 2022

Abbreviation:

COVID-19, coronavirus disease 2019